Talapro-3 could help move Talzenna into earlier prostate cancer.
ApexOnco Front Page
Recent articles
Single, double and even triple-payload ADCs will be presented at the meeting.
Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
A look at big oncology deals since 2016 suggests that there have been more duds than successes.